

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM444846

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release (Reel 5488 / Frame 0344)		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Credit Suisse AG, Cayman Islands Branch		09/21/2017	Bank: SWITZERLAND
RECEIVING PARTY DATA			
Name:	Agere Pharmaceuticals, Inc.		
Street Address:	62925 NE 18th Street		
City:	Bend		
State/Country:	OREGON		
Postal Code:	97701		
Entity Type:	Corporation: SOUTH CAROLINA		
Name:	IRIX Pharmaceuticals, Inc.		
Street Address:	101 Technology Place		
City:	Florence		
State/Country:	SOUTH CAROLINA		
Postal Code:	29501		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	2736131	IRIX	
Registration Number:	2752025	IRIX	
Registration Number:	3046558	IRIX SHARP SOLUTIONS	
Registration Number:	4879490	AGERE	
Registration Number:	5183643	QUADRANT 2	
CORRESPONDENCE DATA			
Fax Number:	8009144240		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	800-713-0755		
Email:	Michael.Violet@wolterskluwer.com		
Correspondent Name:	CT Corporation		
Address Line 1:	4400 Easton Commons Way		

OP \$140.00 2736131

Address Line 2: Suite 125
Address Line 4: Columbus, OHIO 43219

NAME OF SUBMITTER: Doris Ka

SIGNATURE: /Doris Ka/

DATE SIGNED: 09/28/2017

Total Attachments: 4

source=Patheon - Trademark Release (Patheon API Services Inc.)#page1.tif
source=Patheon - Trademark Release (Patheon API Services Inc.)#page2.tif
source=Patheon - Trademark Release (Patheon API Services Inc.)#page3.tif
source=Patheon - Trademark Release (Patheon API Services Inc.)#page4.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this “Release”), dated as of September 21, 2017 (the “Effective Date”), is made by Credit Suisse AG, Cayman Islands Branch, in its capacity as Collateral Agent (the “Agent”), in favor of the grantor parties identified on Schedule I hereto (the “Grantors”).

WHEREAS, pursuant to that certain Security Agreement, dated as of March 11, 2014, by and among the Agent, the Grantors and certain other parties thereto (as amended, amended and restated, or otherwise modified from time to time, the “Security Agreement”), the Grantors granted to the Agent, in its capacity as Agent, a security interest in and to certain collateral;

WHEREAS, pursuant to the Security Agreement, the Grantors executed and delivered a Trademark Short Form Security Agreement, dated as of March 31, 2015 (the “Trademark Security Agreement”), in favor of UBS AG, Stamford Branch (the “Prior Agent”) for recordation with the United States Patent and Trademark Office;

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on March 31, 2015 at Reel/Frame 5488/0344;

WHEREAS, the Agent and the Prior Agent entered into a Notice of Succession of Agency, dated as of June 20, 2017 (the “Succession Agreement”), confirming that the security interest in the collateral originally granted to the Prior Agent under the Trademark Security Agreement, was succeeded by and transferred to the Agent,



WHEREAS, the Succession Agreement was recorded with the United States Patent and Trademark Office on July 17, 2017 at Reel/Frame 6106/0889;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the Trademark Security Agreement, as applicable.
2. Release. The Agent, without representation or warranty of any kind, hereby releases, discharges, terminates, cancels and releases all of its liens, security interests and any other rights in and to the Trademark Collateral, including the trademarks and trademark applications set forth Schedule I attached hereto, arising under the Security Agreement and the Trademark Security Agreement. If and to the extent that the Agent has acquired any right, title or interest in and to the Trademark Collateral under the Trademark Security Agreement, the Agent, hereby re-transfers, re-conveys and re-assigns all such right, title or interest to the Grantors.
3. Termination. The Agent hereby terminates and cancels the Trademark Security Agreement, and the Trademark Security Agreement shall have no further force and effect.
4. Governing Law. This Release shall be governed exclusively under the laws of New York, without regard to conflicts of law or choice of law principles.

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

**CREDIT SUISSE AG, CAYMAN ISLAND
BRANCH, acting in its capacity as Collateral
Agent**

By:  

Name: Doreen Barr Warren Van Heyst
Title: Authorized Signatory Authorized Signatory

[RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY]

**TRADEMARK
REEL: 006164 FRAME: 0135**

Schedule I

Trademarks and Trademark Applications

Mark	Reg. No.	Reg. Date	Registered Owner
IRIX & Design	2,736,131	7/15/2003	IRIX Pharmaceuticals, Inc.
IRIX & Design	2,752,025	8/19/2003	IRIX Pharmaceuticals, Inc.
IRIX SHARP SOLUTIONS & Design	3,046,558	1/17/2006	IRIX Pharmaceuticals, Inc.
AGERE	4,879,490	1/5/2016	Agere Pharmaceuticals, Inc.
QUADRANT 2	5,183,643	4/11/2017	Patheon Development Services, Inc.
[Design]	Abandoned		Agere Pharmaceuticals, Inc.

[RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY]